Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia
Modus Therapeutics Receives Approval for Phase 2 Study Karolinska Development's portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of a pha…